Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Conventional dose melphalan is inactive in metastatic melanoma: results ofan Eastern Cooperative Oncology Group Study (E1687)
Autore:
Hochster, H; Strawderman, MH; Harris, JE; Atkins, MB; Oken, M; Skeel, RT; Jubelirer, SJ; Parkinson, D;
Indirizzi:
NYU, Sch Med, Kaplan Canc Ctr, Med Ctr, New York, NY 10016 USA NYU New York NY USA 10016 aplan Canc Ctr, Med Ctr, New York, NY 10016 USA Rush Presbyterian St Lukes Canc Ctr, Chicago, IL 60612 USA Rush Presbyterian St Lukes Canc Ctr Chicago IL USA 60612 go, IL 60612 USA Beth Israel Deaconess Med Ctr, Boston, MA 02115 USA Beth Israel Deaconess Med Ctr Boston MA USA 02115 r, Boston, MA 02115 USA Univ Minnesota, Minneapolis, MN 55407 USA Univ Minnesota Minneapolis MN USA 55407 nesota, Minneapolis, MN 55407 USA Med Coll Ohio, Toledo, OH 43699 USA Med Coll Ohio Toledo OH USA 43699Med Coll Ohio, Toledo, OH 43699 USA Charleston Area Med Ctr, Charleston, WV 25314 USA Charleston Area Med CtrCharleston WV USA 25314 Charleston, WV 25314 USA NCI, Bethesda, MD 20892 USA NCI Bethesda MD USA 20892NCI, Bethesda, MD 20892 USA
Titolo Testata:
ANTI-CANCER DRUGS
fascicolo: 2, volume: 10, anno: 1999,
pagine: 245 - 248
SICI:
0959-4973(199902)10:2<245:CDMIII>2.0.ZU;2-1
Fonte:
ISI
Lingua:
ENG
Soggetto:
ISOLATED LIMB PERFUSION; ADVANCED MALIGNANT-MELANOMA; BONE-MARROW SUPPORT; CHEMOTHERAPY;
Keywords:
Eastern Cooperative Oncology Group; melanoma; melphalan;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
15
Recensione:
Indirizzi per estratti:
Indirizzo: Hochster, H NYU,NYch Med, Kaplan Canc Ctr, Med Ctr, 160 E 32nd St,2nd Floor, New York, NYU 160 E 32nd St,2nd Floor New York NY USA 10016 r, New York,
Citazione:
H. Hochster et al., "Conventional dose melphalan is inactive in metastatic melanoma: results ofan Eastern Cooperative Oncology Group Study (E1687)", ANTI-CANC D, 10(2), 1999, pp. 245-248

Abstract

Despite reports that i.v. melphalan is active in the settings of conditioning regimens utilizing high-dose chemotherapy for autologous bone marrow transplantation and in isolated limb perfusion for the treatment of malignantmelanoma, its activity at conventional doses has never been defined in this disease. We conducted a phase II study of conventional-dose i.v. melphalan (30 mg/m(2)) in 17 patients with metastatic melanoma. All patients were previously untreated with chemotherapy with performance status 0, 1 or 2. Forty seven cycles were given with a median of two cycles. One patient was not evaluable due to early death. There were no responses in the 16 patients,resulting in a 0% response rate (95% confidence interval = 0-17%). We conclude that conventional-dose melphalan by i.v. administration has no appreciable activity in patients with metastatic malignant melanoma. [(C) 1999 Lippincott Williams & Wilkins.].

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 20/10/20 alle ore 05:44:44